Single User License
INR 236460
Site License
INR 472920
Corporate User License
INR 709380

Service Tax Additional

select a format
Price

Single User License
USD 3500
Site License
USD 7000
Corporate User License
USD 10500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Pipeline Review, H2 20

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Pipeline Review, H2 20


  Request for Sample Report

Executive Summary

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Pipeline Review, H2 2016', provides in depth analysis on C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted pipeline therapeutics.

The report provides comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)

The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects

The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Overview 10

Therapeutics Development 11

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Products under Development by Stage of Development 11

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Products under Development by Therapy Area 12

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Products under Development by Indication 13

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Products under Development by Companies 17

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Products under Development by Universities/Institutes 21

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Therapeutics Assessment 23

Assessment by Monotherapy/Combination Products 23

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Companies Involved in Therapeutics Development 30

AdAlta Pty Ltd. 30

Ambrx, Inc. 31

BioLineRx, Ltd. 32

Bristol-Myers Squibb Company 33

Eli Lilly and Company 34

Globavir Biosciences, Inc. 35

GlycoMimetics, Inc. 36

Juventas Therapeutics, Inc. 37

Pharis Biotec GmbH 38

Polyphor Ltd. 39

TaiGen Biotechnology Co., Ltd. 40

Upsher-Smith Laboratories, Inc. 41

X4 Pharmaceuticals, Inc. 42

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Drug Profiles 43

AD-114-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

ALB-408-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

AM-3114-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

balixafortide-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

BL-8040-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

burixafor-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

GBV-4086-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

GMI-1359-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

HPH-112-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

HPH-196-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

HPH-211-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

hz-515H7-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

JVS-100-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

LY-2510924-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Monoclonal Antibody to Antagonize CXCR4 for Breast Cancer-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

POL-5551-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Protein to Agonize CXCR4 for Inflammation-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

PTX-9908-Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Q-122-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Recombinant Protein to Antagonize CXCR4 for Oncology-Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Recombinant Proteins to Antagonize CXCR4 for Oncology and Autoimmune Disorders-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Synthetic Peptide to Target CXCR4 and SDF-1 for HIV-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

ulocuplumab-Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

USL-311-Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

X-4P001-Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

X-4P002-Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Dormant Projects 89

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Discontinued Products 94

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)-Featured News & Press Releases 95

Oct 14, 2016: AdAlta update on Orphan Drug Designation application for lead drug targeting idiopathic pulmonary fibrosis 95

Oct 05, 2016: BioLineRx Announces Acceptance of BL-8040 Abstracts for Oral and Poster Presentations at 58th American Society of Hematology (ASH) Annual Meeting 95

Sep 27, 2016: X4 Pharmaceuticals Announces Initiation of Phase 1b Study of X4P-001 in Patients with Resectable Stage III and Stage IV Melanoma 96

Sep 20, 2016: BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA(pembrolizumab) for Treatment of Pancreatic Cancer 96

Sep 12, 2016: AdAlta signs agreement with FujiFilm Diosynth Biotechnologies to begin manufacturing its lead fibrosis drug candidate 97

Sep 08, 2016: BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference 98

Sep 06, 2016: GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359 99

Jun 28, 2016: BioLineRx Announces Regulatory Submissions for Phase 2a Trial of BL-8040 in Combination with KEYTRUDA (pembrolizumab) for Treatment of Pancreatic Cancer 99

May 25, 2016: GlycoMimetics plans to file IND application for GMI-1359 100

May 19, 2016: BioLineRx BL-8040 to be Presented at Upcoming Scientific Conferences 101

May 16, 2016: Upsher-Smith Announces Start Of First In Human Clinical Trial In Oncology With Novel CXCR4 Antagonist USL311 101

May 09, 2016: X4 Pharmaceuticals Announces Initiation of Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma 102

Apr 19, 2016: BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016 102

Apr 19, 2016: X4 Pharmaceuticals Announces Data Presentation for Lead Candidate X4P-001 at AACR Annual Meeting 103

Mar 29, 2016: BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML 104

Appendix 107

Methodology 107

Coverage 107

Secondary Research 107

Primary Research 107

Expert Panel Validation 107

Contact Us 107

Disclaimer 108

List of Figures

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Top 10 Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Mechanism of Actions, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 28

List of Tables

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Development by Companies, H2 2016 (Contd..2) 20

Number of Products under Investigation by Universities/Institutes, H2 2016 21

Products under Investigation by Universities/Institutes, H2 2016 22

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Pipeline by AdAlta Pty Ltd., H2 2016 30

Pipeline by Ambrx, Inc., H2 2016 31

Pipeline by BioLineRx, Ltd., H2 2016 32

Pipeline by Bristol-Myers Squibb Company, H2 2016 33

Pipeline by Eli Lilly and Company, H2 2016 34

Pipeline by Globavir Biosciences, Inc., H2 2016 35

Pipeline by GlycoMimetics, Inc., H2 2016 36

Pipeline by Juventas Therapeutics, Inc., H2 2016 37

Pipeline by Pharis Biotec GmbH, H2 2016 38

Pipeline by Polyphor Ltd., H2 2016 39

Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016 40

Pipeline by Upsher-Smith Laboratories, Inc., H2 2016 41

Pipeline by X4 Pharmaceuticals, Inc., H2 2016 42

Dormant Projects, H2 2016 89

Dormant Projects (Contd..1), H2 2016 90

Dormant Projects (Contd..2), H2 2016 91

Dormant Projects (Contd..3), H2 2016 92

Dormant Projects (Contd..4), H2 2016 93

Discontinued Products, H2 2016 94

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AdAlta Pty Ltd., Ambrx, Inc., BioLineRx, Ltd., Bristol-Myers Squibb Company, Eli Lilly and Company, Globavir Biosciences, Inc., GlycoMimetics, Inc., Juventas Therapeutics, Inc., Pharis Biotec GmbH, Polyphor Ltd., TaiGen Biotechnology Co., Ltd., Upsher-Smith Laboratories, Inc., X4 Pharmaceuticals, Inc.

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Therapeutic Products under Development, Key Players in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Therapeutics, C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Pipeline Overview, C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Pipeline, C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com